Blood Eosinophils, Exhaled Nitric Oxide, And IgE Do Not Accurately Predict Sputum Eosinophils

Author(s):  
Annette T. Hastie ◽  
Wendy C. Moore ◽  
Huashi Li ◽  
Brian M. Rector ◽  
Rodolfo M. Pascual ◽  
...  
2012 ◽  
Vol 10 (3) ◽  
pp. 383-392 ◽  
Author(s):  
M. Malerba ◽  
B. Ragnoli ◽  
A. Radaeli ◽  
F.L.M. Ricciardolo

Current approaches to control asthma do not involve direct assessment of airway inflammation. The aim of this study is to assess whether the therapeutic adjustments of steroid treatment according to a stepwise algorithm based on sputum Eosinophils (sEos) and fractioned exhaled Nitric Oxide (FeNO) were effective in maintaining the stability of a group of stable asthmatic patients during a twelvemonth follow-up. Fourteen asthmatic patients, treated for asthma according to a previously published protocol, were enrolled in the study. The patients underwent clinical evaluation, pulmonary function tests, measuring of airway hyperresponsiveness to methacholine, and determination of FeNO and sEos at visit 1. These procedures were repeated after 6 and 12 months (Visits 2 and 3, respectively). Symptoms score gradually improved during the study (p=0.008), no changes were observed in the frequency of clinical asthma exacerbations or in airway hyperresponsiveness to methacholine. At the end of the study both sEos and FeNO were significantly improved (p=0.011 and p=0.003, respectively) and at visit 3 the median steroid dose was reduced (p=0.039) in accordance with the improving of symptoms score, FeNO and sEos values. A direct relationship was observed between the difference of FeNO values and the difference of sEos registered between visits 1 and 2 (r2=609, p0.001) and between visits 2 and 3 (r2=646, p<0.001). In conclusion, long-term titration of asthma inhaled steroid treatment based on sEos and FeNO values was able to provide long-term clinical stability and improvement to the asthmatic patients studied, without significant increases in the steroid dose.


2018 ◽  
Vol Volume 13 ◽  
pp. 2525-2532 ◽  
Author(s):  
Yusuke Takayama ◽  
Hiroshi Ohnishi ◽  
Fumiya Ogasawara ◽  
Kosuke Oyama ◽  
Tetsuya Kubota ◽  
...  

2015 ◽  
Vol 21 (32) ◽  
pp. 4752-4762 ◽  
Author(s):  
Mario Malerba ◽  
Alessandro Radaeli ◽  
Alessia Olivini ◽  
Beatrice Ragnoli ◽  
Fabio Ricciardolo ◽  
...  

2013 ◽  
Vol 188 (3) ◽  
pp. 400-402 ◽  
Author(s):  
Louise Fleming ◽  
Lemonia Tsartsali ◽  
Nicola Wilson ◽  
Nicolas Regamey ◽  
Andrew Bush

Thorax ◽  
2018 ◽  
Vol 73 (12) ◽  
pp. 1110-1119 ◽  
Author(s):  
Helen L Petsky ◽  
Chris J Cates ◽  
Kayleigh M Kew ◽  
Anne B Chang

BackgroundAsthma guidelines guide health practitioners to adjust treatments to the minimum level required for asthma control. As many people with asthma have an eosinophilic endotype, tailoring asthma medications based on airway eosinophilic levels (sputum eosinophils or exhaled nitric oxide, FeNO) may improve asthma outcomes.ObjectiveTo synthesise the evidence from our updated Cochrane systematic reviews, for tailoring asthma medication based on eosinophilic inflammatory markers (sputum analysis and FeNO) for improving asthma-related outcomes in children and adults.Data sourcesCochrane reviews with standardised searches up to February 2017.Study selectionThe Cochrane reviews included randomised controlled comparisons of tailoring asthma medications based on sputum analysis or FeNO compared with controls (primarily clinical symptoms and/or spirometry/peak flow).ResultsThe 16 included studies of FeNO-based management (seven in adults) and 6 of sputum-based management (five in adults) were clinically heterogeneous. On follow-up, participants randomised to the sputum eosinophils strategy (compared with controls) were significantly less likely to have exacerbations (62 vs 82/100 participants with ≥1 exacerbation; OR 0.36, 95% CI 0.21 to 0.62). For the FeNO strategy, the respective numbers were adults OR 0.60 (95% CI 0.43 to 0.84) and children 0.58 (95% CI 0.45 to 0.75). However, there were no significant group differences for either strategy on daily inhaled corticosteroids dose (at end of study), asthma control or lung function.ConclusionAdjusting treatment based on airway eosinophilic markers reduced the likelihood of asthma exacerbations but had no significant impact on asthma control or lung function.


Thorax ◽  
2010 ◽  
Vol 67 (3) ◽  
pp. 199-208 ◽  
Author(s):  
H L Petsky ◽  
C J Cates ◽  
T J Lasserson ◽  
A M Li ◽  
C Turner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document